علاج سرطان الخلايا الكبدية المتقدم مع زراعة كبد سابقة عند موانع استخدام العلاج المناعي

References

1. Patients with Child-Turcotte-Pugh A cirrhosis in whom atezolizumab plus bevacizumab and durvalumab plus tremelimumab are contraindicated should be offered first-line sorafenib or lenvatinib (Level 1, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466
2. AASLD advises against the use of ICIs in patients with recurrent HCC after liver transplantation given increased risk of graft loss and death (Level 4, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466
3. AASLD advises cabozantinib or regorafenib (or ramucirumab in patients with AFP ≥ 400 ng/ml) as preferred agents after sorafenib or lenvatinib if patients are not eligible for clinical trials (Level 1, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466